Antibiotic resistance rates in causative agents of infections in diabetic patients: Rising concerns

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 4, 2013, Pages 411-420

  Boyanova, Lyudmila ^a   Mitov, Ivan ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

diabetes; diabetic foot infection; hyperglycemia; infection; methicillin resistant Staphylococcus aureus; multidrug resistant; Mycobacterium tuberculosis; prophylaxis; risk; treatment

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CEFIXIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; GATIFLOXACIN; GENTAMICIN; GLITAZONE DERIVATIVE; GLUCOSE; IMIPENEM; INSULIN; LINCOSAMIDE; MACROLIDE; METALLO BETA LACTAMASE; METFORMIN; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; STREPTOGRAMIN DERIVATIVE; SULFONYLUREA; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BLOOD GLUCOSE MONITORING; CELLULITIS; DIABETES MELLITUS; DIABETIC FOOT; DRUG PENETRATION; DRUG USE; EARLY DIAGNOSIS; EMPHYSEMATOUS CHOLECYSTITIS; EMPHYSEMATOUS PYELONEPHRITIS; EXTERNAL OTITIS; GLYCEMIC CONTROL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HELICOBACTER PYLORI; HUMAN; HYPERGLYCEMIA; IMMUNOCOMPROMISED PATIENT; INFECTION; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OSTEOMYELITIS; OUTCOME ASSESSMENT; PERITONITIS; PSEUDOMONAS AERUGINOSA; RECURRENT INFECTION; REVIEW; RISK REDUCTION; SEPSIS; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MICROBIAL SENSITIVITY TESTS; OPPORTUNISTIC INFECTIONS; PROBIOTICS;

EID: 84879902986     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.13.19     Document Type: Review

References (79)

1. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med. J. 27(4), 269-273 (2012).
2. Sacks DB, Arnold M, Bakris GL et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 57(6), e1-e47 (2011).
3. Knapp S. Diabetes and infection: is there a link? - A mini-review. Gerontology 59(2), 99-104 (2013).
4. Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J. Gastroenterol. 15(33), 4137-4142 (2009).
5. Pettersson US, Christoffersson G, Massena S et al. Increased recruitment but impaired function of leukocytes during inflammation in mouse models of Type 1 and Type 2 diabetes. PLoS ONE 6(7), e22480 (2011).
6. Koh GC, Peacock SJ, van der Poll T, Wiersinga WJ. The impact of diabetes on the pathogenesis of sepsis. Eur. J. Clin. Microbiol. Infect. Dis. 31(4), 379-388 (2012).
7. Preshaw PM, Alba AL, Herrera D et al. Periodontitis and diabetes: a two-way relationship. Diabetologia 55(1), 21-31 (2012).
8. Arya AK, Pokharia D, Kumar H, Mishra M, Tripathi K. Impact of lymphocyte apoptosis in diabetes mellitus. Asian J. Med. Sci. 2, 1-6 (2011).
9. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J. Allergy Clin. Immunol. 125(2 Suppl. 2), S195-S203 (2010).
10. Viardot A, Grey ST, Mackay F, Chisholm D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology 148(1), 346-353 (2007).
11. Farnworth E, Roberts A, Rangaraj A, Minhas U, Holloway S, Harding K. Tetanus in patients with chronic wounds - are we aware? Int. Wound J. 9(1), 93-99 (2012).
12. Hair PS, Echague CG, Rohn RD, Krishna NK, Nyalwidhe JO, Cunnion KM. Hyperglycemic conditions inhibit C3-mediated immunologic control of Staphylococcus aureus. J. Transl. Med. 10, 35 (2012).
13. Sen T, Joshi SR, Udwadia ZF. Tuberculosis and diabetes mellitus: merging epidemics. J. Assoc. Physicians India 57, 399-404 (2009).
14. Jeon CY, Harries AD, Baker MA et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop. Med. Int. Health 15(11), 1300-1314 (2010).
15. Magee MJ, Blumberg HM, Narayan KM. Commentary: co-occurrence of tuberculosis and diabetes: new paradigm of epidemiological transition. Int. J. Epidemiol. 40(2), 428-431 (2011).
16. Banerjee D, Sharma P. Dual effect of glucose on macrophage NADPH oxidase activity: a possible link between diabetes and tuberculosis. Oxid. Antioxid. Med. Sci. 1(2), 91-96 (2012).
17. Rawat V, Singhai M, Kumar A, Jha PK, Goyal R. Bacteriological and resistance profile in isolates from diabetic patients. N. Am. J. Med. Sci. 4(11), 563-568 (2012).
18. Venmans LM, Hak E, Gorter KJ, Rutten GE. Incidence and antibiotic prescription rates for common infections in patients with diabetes in primary care over the years 1995 to 2003. Int. J. Infect. Dis. 13(6), e344-e351 (2009).
19. Hirji I, Guo Z, Andersson SW, Hammar N, Gomez-Caminero A. Incidence of urinary tract infection among patients with Type 2 diabetes in the UK General Practice Research Database (GPRD). J. Diabetes Complicat. 26(6), 513-516 (2012).
20. Taganna J, de Boer AR, Wuhrer M, Bouckaert J. Glycosylation changes as important factors for the susceptibility to urinary tract infection. Biochem. Soc. Trans. 39(1), 349-354 (2011).
21. Gorter KJ, Hak E, Zuithoff NP, Hoepelman AI, Rutten GE. Risk of recurrent acute lower urinary tract infections and prescription pattern of antibiotics in women with and without diabetes in primary care. Fam. Pract. 27(4), 379-385 (2010).
22. Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care 34(1), 230-235 (2011).
23. Liao H, Zakhaleva J, Chen W. Cells and tissue interactions with glycated collagen and their relevance to delayed diabetic wound healing. Biomaterials 30(9), 1689-1696 (2009).
24. Mori S, Takahashi HK, Liu K et al. Ciprofloxacin inhibits advanced glycation end products-induced adhesion molecule expression on human monocytes. Br. J. Pharmacol. 161(1), 229-240 (2010).
25. Richard JL, Sotto A, Lavigne JP. New insights in diabetic foot infection. World J. Diabetes 2(2), 24-32 (2011).
26. Roberts AD, Simon GL. Diabetic foot infections: the role of microbiology and antibiotic treatment. Semin. Vasc. Surg. 25(2), 75-81 (2012).
27. Endorf FW, Cancio LC, Klein MB. Necrotizing soft-tissue infections: clinical guidelines. J. Burn Care Res. 30(5), 769-775 (2009).
28. Ustin JS, Malangoni MA. Necrotizing soft-tissue infections. Crit. Care Med. 39(9), 2156-2162 (2011).
29. Sereno M, Gómez-Raposo C, Gutiérrez-Gutiérrez G, López-Gómez M, Casado E. Severe emphysematous cystitis: outcome after seven days of antibiotics. Mcgill J. Med. 13(1), 13 (2011).
30. Lo YC, Chuang YW, Lin YH. Yokenella regensburgei in an immunocompromised host: a case report and review of the literature. Infection 39(5), 485-488 (2011).
31. Chen XY, Xu F, Xia JY, Cheng YS, Yang Y. Bacteremia due to Rhodococcus equi: a case report and review of the literature. J. Zhejiang Univ. Sci. B. 10(12), 933-936 (2009).
32. Grimaldi D, Doloy A, Fichet J et al. Necrotizing fasciitis and septic shock related to the uncommon Gram-negative pathogen Sphingobacterium multivorum. J. Clin. Microbiol. 50(1), 202-203 (2012).
33. Chao CM, Gau SJ, Lai CC. Aeromonas genitourinary tract infection. J. Infect. 65(6), 573-575 (2012).
34. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32(7), 1335-1343 (2009).
35. Nitzan O, Low M, Lavi I, Hammerman A, Klang S, Raz R. Variability in outpatient antimicrobial consumption in Israel. Infection 38(1), 12-18 (2010).
36. Lipsky BA, Peters EJ, Senneville E et al. Expert opinion on the management of infections in the diabetic foot. Diabetes Metab. Res. Rev. 28(Suppl. 1), 163-178 (2012).
37. Basu S, Ramchuran Panray T, Bali Singh T, Gulati AK, Shukla VK. A prospective, descriptive study to identify the microbiological profile of chronic wounds in outpatients. Ostomy. Wound. Manage. 55(1), 14-20 (2009).
38. Njunda AL, Assob NJC, Nsagha SD et al. Uropathogens from diabetic patients with asymptomatic bacteriuria and urinary tract infections. Sci. J. Microbiol. 1(6), 141-146 (2012).
39. Suto C, Morinaga M, Yagi T, Tsuji C, Toshida H. Conjunctival sac bacterial flora isolated prior to cataract surgery. Infect. Drug Resist. 5, 37-41 (2012).
40. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 53(5), 914-923 (2010).
41. Satola SW, Lessa FC, Ray SM et al.; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. aureus phenotype. J. Clin. Microbiol. 49(4), 1583-1587 (2011).
42. Menne EN, Sonabend RY, Mason EO et al. Staphylococcus aureus infections in pediatric patients with diabetes mellitus. J. Infect. 65(2), 135-141 (2012).
43. Rabinowitz RP, Kufera JA, Makley MJ. A hidden reservoir of methicillin-resistant Staphylococcus aureus and vancomycinresistant Enterococcus in patients newly admitted to an acute rehabilitation hospital. PMR 4(1), 18-22 (2012).
44. Saber MH, Barai L, Haq JA, Jilani MSA, Begum MJ. The pattern of organism causing urinary tract infection in diabetic and non diabetic patients in Bangladesh. Bangladesh J. Med. Microbiol. 4(1), 6-8 (2010).
45. Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum β-lactamase (ESBL)-producing enterobacteria. Int. J. Clin. Pract. 66(9), 891-896 (2012).
46. Borer A, Saidel-Odes L, Eskira S et al. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K. pneumoniae. Am. J. Infect. Control 40(5), 421-425 (2012).
47. Ariza X, Castellote J, Lora-Tamayo J et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J. Hepatol. 56(4), 825-832 (2012).
48. Vinodkumar CS, Hiresave S, Kandagal Giriyapal B, Bandekar N. Metallo-β lactamase producing Pseudomonas aeruginosa and its association with diabetic foot. Indian J. Surg. 73(4), 291-294 (2011).
49. Zubair M, Malik A, Ahmad J. Prevalence of metallo-β-lactamase- producing Pseudomonas aeruginosa isolated from diabetic foot ulcer patients. Diabetes Metab. Syndr. 5(2), 90-92 (2011).
50. Sivanmaliappan TS, Sevanan M. Antimicrobial susceptibility patterns of Pseudomonas aeruginosa from diabetes patients with foot ulcers. Int. J. Microbiol. 2011, 605195 (2011).
51. Prata-Rocha ML, Gontijo-Filho PP, Melo GB. Factors influencing survival in patients with multidrug-resistant Acinetobacter baumannii infection. Braz. J. Infect. Dis. 16(3), 237-241 (2012).
52. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. J. Korean Med. Sci. 27(5), 471-475 (2012).
53. Velásquez GE, Yagui M, Cegielski JP et al. Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008. Emerging Infect. Dis. 17(3), 432-440 (2011).
54. Baker MA, Harries AD, Jeon CY et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 9, 81 (2011).
55. Tseng CH. Diabetes, insulin use and Helicobacter pylori eradication: a retrospective cohort study. BMC Gastroenterol. 12
56. Demir M, Gokturk HS, Ozturk NA, Arslan H, Serin E, Yilmaz U. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in Type 2 diabetes mellitus patients. South. Med. J. 102(11), 1116-1120 (2009).
57. Ojetti V, Pellicano R, Fagoonee S, Migneco A, Berrutti M, Gasbarrini A. Helicobacter pylori infection and diabetes. Minerva Med. 101(2), 115-119 (2010).
58. Demir M, Göktürk S, Oztürk NA, Serin E, Yilmaz U. Bismuth-based first-line therapy for Helicobacter pylori eradication in Type 2 diabetes mellitus patients. Digestion 82(1), 47-53 (2010).
59. Boyanova L, Ilieva J, Gergova G et al. Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of Helicobacter pylori in Bulgaria. J. Med. Microbiol. 58(Pt 1), 94-100 (2009).
60. Al Benwan K, Al Mulla A, Rotimi VO. A study of the microbiology of diabetic foot infections in a teaching hospital in Kuwait. J. Infect. Public Health 5(1), 1-8 (2012).
61. Neto RM, Ansaldi MA Jr, da Costa ME, da Silva SO Jr, Luz VH. A case report of a multi-drug resistant bacterial infection in a diabetic patient treated in northeast Brazil. Diabet. Foot Ankle doi:10.3402/dfa. v3i0.18656 (2012) (Epub ahead of print).
62. Nataraj G. New Delhi metallo-β-lactamase: what is in a name? J. Postgrad. Med. 56(4), 251-252 (2010).
63. Struelens MJ, Monnet DL, Magiorakos AP, Santos O'Connor F, Giesecke J; European NDM-1 Survey Participants. New Delhi metallo-β-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill. 15(46), (2010).
64. Peirano G, Ahmed-Bentley J, Woodford N, Pitout JD. New Delhi metallo-β-lactamase from traveler returning to Canada. Emerging Infect. Dis. 17(2), 242-244 (2011).
65. Brink AJ, Coetzee J, Clay CG et al. Emergence of New Delhi metallo-β-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa. J. Clin. Microbiol. 50(2), 525-527 (2012).
66. Moghissi ES. Reexamining the evidence for inpatient glucose control: new recommendations for glycemic targets. Am. J. Health. Syst. Pharm. 67(16 Suppl 8), S3-S8 (2010).
67. Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven AJ, van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop. Med. Int. Health 15(11), 1289-1299 (2010).
68. Koromantzos PA, Makrilakis K, Dereka X, Katsilambros N, Vrotsos IA, Madianos PN. A randomized, controlled trial on the effect of non-surgical periodontal therapy in patients with Type 2 diabetes. Part I: effect on periodontal status and glycaemic control. J. Clin. Periodontol. 38(2), 142-147 (2011).
69. Serrano C, Pérez C, Sabogal D. Effect of periodontal therapy on metabolic control and an inflammatory mediator in Type 2 diabetic subjects: a report on 17 consecutive cases. J. Int. Acad. Periodontol. 14(2), 26-34 (2012).
70. Sehgal R, Berg A, Figueroa R et al. Risk factors for surgical site infections after colorectal resection in diabetic patients. J. Am. Coll. Surg. 212(1), 29-34 (2011).
71. Dalla Paola L, Carone A, Ricci S, Russo A. Advances in treatment of diabetic foot ulcers. Av. Diabetol. 26(5), 296-305 (2010).
72. Lipsky BA, Berendt AR, Cornia PB et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 54(12), e132-e173 (2012).
73. Napolitano LM. Severe soft tissue infections. Infect. Dis. Clin. North Am. 23(3), 571-591 (2009).
74. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 4(9), e6914 (2009).
75. Schintler MV, Traunmüller F, Metzler J et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J. Antimicrob. Chemother. 64(3), 574-578 (2009).
76. Cruz F, Dambros M, Naber KG, Bauer HV, Cozma G. Recurrent urinary tract infections: Uro-Vaxom®, a new alternative. Eur. Urol. Suppl. 8(9), 762-768 (2009).
77. Gould FK, Brindle R, Chadwick PR et al.; MRSA Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J. Antimicrob. Chemother. 63(5), 849-861 (2009).
78. Fernández Ospina NH, Jiménez González S, Carrascosa Romero E, García Morales E, Lázaro Martínez JL. Activated carbon and silver biocide dressings for diabetic foot. A descriptive analysis. Rev. Enferm. 32(1), 8-12 (2009).
79. Kaur IP, Kuhad A, Garg A, Chopra K. Probiotics: delineation of prophylactic and therapeutic benefits. J. Med. Food 12(2), 219-235 (2009).